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Evidence Based Medicine
What are the current therapeutic options for haemorrhagic strokes?
Maria Khan, Ayeesha Kamran Kamal
Department of Neurology, Director Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan.

The Factor Seven for Acute Haemorrhagic Stroke
Trial (FAST) and Intensive Blood Pressure Reduction in
Acute Cerebral Haemorrhage trial (INTERACT).

Why are these studies important and
noteworthy?
Intracerebral haemorrhage (ICH) is the most
devastating form of stroke carrying a mortality of up to 40%
at one month. In our part of the world the levels of
uncontrolled hypertension pose a greater risk of ICH for our
population where ICH is about 30% of all strokes compared
to 14% in developed countries.
There is evidence to suggest that haematoma
expansion occurs in as many as 70% of patients. This
expansion translates into increased disability and death.
Most of this expansion is within the initial three hours. Also
early elevation of blood pressure (BP) is very common after
ICH and many studies have highlighted an association
between elevated BP post ICH and poor outcomes. The
reason for this is postulated to be an increase in both the size
of the haematoma and perilesional oedema.
Factor VIIa activates factor X on the surface of
activated platelets and leads to accelerated coagulation and
thus limits rebleed and haematoma expansion. A prior study
(published in NEJM in 2005) had demonstrated that
recombinant activated Factor VII (rFVIIa) when given
within four hours of symptom onset limited the growth of
ICH. In the FAST trial, the investigators evaluated the
effects of two dose of rFVIIa on rates of death and disability
after ICH.
The Intensive Blood Pressure Reduction In Acute
Cerebral Haemorrhage Trial (INTERACT) was a
randomized controlled trial undertaken to determine the
effects of early intensive BP lowering on haematoma
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growth and perihaematomal oedema. A pilot phase of this
study had demonstrated that such lowering of BP was safe
and limited haematoma expansion in patients treated within
six hours of symptom onset. In the next phase the authors
have reported the effects of early intensive BP lowering on
haematoma growth over 72 hours and also investigated the
effects of this treatment on perihaematomal oedema. A third
phase of the study is currently underway to assess whether
this therapy translates into clinical benefit or not.

Who were the participants?
The FAST trial was a multicenter, randomized,
double- blind, placebo- controlled trial conducted between
May 2005 and February 2007 at 122 sites in 22 countries.
Most of these were European countries and the US, with no
contribution from South East Asia. China and Singapore
contributed small numbers. Patients older than 18 years
with acute ICH documented by CT within 3 hours of
symptom onset were eligible to get enrolled. They excluded
patients who had a GCS of 5 or less (indicating severe ICH),
those who had a surgical evacuation planned within 24
hours, those who were on anticoagulation and those who
had a history of recent thromboembolism (and therefore
contraindication to rFVIIa).
For INTERACT 404 patients were recruited form
a network of hospital sites in China, South Korea, and
Australia during 2005 and 2007. They include patients
>18 years of age with CT confirmed spontaneous ICH
and elevated systolic BP (>2 readings of >150 and <220
mm Hg recorded >2 min apart). A prerequisite was the
capacity to start randomly assigned treatment within 6
hours of ICH in a monitored environment. They excluded
patients with a clear indication or contraindication to BP
lowering, those with a recent ischaemic stroke, those
who were deeply comatose or were planned for an early
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neurosurgical intervention.

What was the intervention?
In FAST the patients underwent block randomization
according to site to receive a single intravenous dose of
placebo (268 patients) or of rFVIIa at a dose of 20 µg (276
patients) or 80 µg (297 patients) per kilogram. Treatment
was administered within 1 hour after the baseline CT scan
and no later than 4 hours after the onset of symptoms.
Follow up CT scans were performed at 24 and 72 hours and
volumes of intracerebral haemorrhage, intraventricular
haemorrhage, and oedema were calculated. The primary
outcome measure was the score on mRS at day 90.
In INTERACT, patients were randomly assigned to
receive either an early intensive BP-lowering treatment
strategy (203 patients) or the recommended best practice
standard of BP lowering (201 patients) at the time that of the
American Heart Association guidelines published in 1999.
For patients allocated to the intensive group, the goal was to
achieve a systolic BP of 140 mm Hg within 1 hour of
randomization and subsequently to maintain this target level
for the next 7 days. For patients allocated to the guideline
group, treatment was recommended to achieve a target
systolic BP of 180 mm Hg. The outcomes for the present
investigation were the absolute and proportional increases
in haematoma and perihaematomal oedema volumes during
the first 72 hours after ICH. CT was repeated at 24 and 72
hours of symptom onset. For this 151 patients were included
from the intensive arm and 145 from the standard care arm,
as the rest did not have 3 CT scans.

What was the outcome?
In FAST the estimated mean increase in the volume
of intracerebral haemorrhage was 26% in the placebo group
and 11% in the group receiving 80 µg of rFVIIa per
kilogram thus proving that factor VI does limit haematoma
expansion. The increase in the volume of haematoma was
3.8 ml less in the group receiving 80 µg of rFVIIa than in
the placebo group (95% confidence interval [CI], 6.7 to 0.9;
P = 0.009). The intraventricular haemorrhage volume
doubled in the placebo arm but remained unchanged in the
factor VII arms, but this difference did not reach statistical
significance and the final lesion volumes were also similar
in the three groups. Despite the significant haematoma
expansion in the placebo arm compared to the active arm,
the primary outcome measure (the proportion of patients
who died or were severely disabled) did not differ
significantly among the three groups. The distribution of
outcomes on the modified Rankin scale and the median
scores on the Barthel index were similar among the three
groups. However, there was an absolute increase of 5% in
the frequency of arterial thromboembolic serious adverse
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events in the group receiving 80 µg of rFVIIa per kilogram
as compared with the placebo group (P = 0.04).
In INTERACT, early intensive BP lowering
significantly reduced BP levels during the treatment. Compared
with the guideline group, the intensive group showed significant
differences of 3.15 mL (95% CI, 1.00 to 5.30 mL; P=0.004) and
2.45 mL (95% CI, 0.75 to 4.16 mL; P=0.005) less mean
absolute haematoma growth at 24 and 72 hours, respectively.
The mean difference in absolute increase over 72 hours was
2.80 mL (95% CI, 1.04 to 4.56 mL; P=0.002). However, there
was no significant difference in the mean perihaematomal
oedema growth between the two groups.

What were the conclusions?
In FAST, rFVIIa given within 4 hours after the
onset of symptoms of intracerebral haemorrhage
significantly reduced growth of the haematoma but failed
to improve survival or functional outcome at 90 days.
There was also an absolute increase of 5% in arterial
thromboembolic serious adverse events in the group
receiving 80 µg of rFVIIa per kilogram as compared with
the placebo group (9% vs. 4%). Although this is a negative
trial there are some important things that need to be
considered. Firstly, there were important randomization
imbalances in the trial. Secondly, the patients who were
included had relatively small haemorrhages (mean
volume~22-24 ml) and were neurologically very intact
with GCS of 14 and NIHSS of around 13. What is not
known is whether those with larger haemorrhages or those
with higher risk of re-bleed for various reasons would
benefit more from this therapy.
INTERACT has demonstrated that early intensive
BP lowering does attenuate haematoma growth in patients
with ICH. It does not have a significant effect on the growth
of perihaematomal oedema. Whether this radiological
finding translates into clinical benefit is yet to be evaluated.

Do corticosteroids have a role in ICH?
A Cochrane review published in 2008 on use of
corticosteroids in primary ICH concluded that there is no
evidence of a beneficial or adverse effect of corticosteroids
in patients with ICH whereas there is some evidence that
corticosteroids increase the risk of serious adverse effects.

How does this impact our clinical practice?
Before FAST and INTERACT, there was little data
regarding therapy in ICH. Now at least targets have been
identified. Recombinant factor VIIa shows promise but it
needs to be evaluated in patients with larger haematomas
and in those with higher risk of re-bleed. Till then its use is
not recommended.
J Pak Med Assoc

Early intensive BP lowering also has impact on
limiting haematoma growth. But till the next phase of this
trial is completed, we cannot conclude whether this
translates into clinical benefit or not. Besides this kind of
aggressive BP management requires dedicated stroke units
which in our current setup are not available. Till more data
comes out, standard recommendations for ICH management
should be followed.
Corticosteroid use is very frequent in our setup.
What must be borne in mind is that there is no evidence
to suggest their benefits and they carry a risk of adverse
effects. Therefore their use is not recommended in
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patients with ICH.
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